Policy & Community Health
Healthcare Policy Developments
Factual, balanced coverage of policy developments that affect pharmacy practice.
Healthcare Policy Developments at a glance
- About this topic
- Factual, balanced coverage of policy developments that affect pharmacy practice.
- In the Knowledge Hub
- Content on this topic is in development.
- Live intelligence
- Tracked from official sources on PBMs & reimbursement, GLP-1 pricing, coverage & access, Drug advertising & marketing enforcement and Telehealth prescribing & medication delivery.
- Latest official record
- Request for Information (RFI): Pharmacy Benefit Manager Compensation and Data Collection (opens the source in a new tab) (Federal Register, Jun 17, 2026)
General professional education. Not accredited continuing education, and not clinical, legal or financial advice.
Articles and resources
Content on this topic is in development
We publish carefully and only when content is genuinely useful. Get updates when new insights are published, or propose a contribution.
What is changing in this area right now?
Topic intelligenceOfficial records and reference tools from NPHLA Intelligence on the subjects closest to this topic.
- PBMs & reimbursement
- GLP-1 pricing, coverage & access
- Drug advertising & marketing enforcement
- Telehealth prescribing & medication delivery
- Request for Information (RFI): Pharmacy Benefit Manager Compensation and Data Collection (opens the source in a new tab)
This request for information (RFI) solicits technical input on the services and business practices of pharmacy benefit managers ("PBMs") and their affiliates to inform implementation of recent legislation. It specifically focuses on gathering information to inform two specific…
- Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications (opens the source in a new tab)
The Drug Enforcement Administration (DEA) jointly with the Department of Health and Human Services (HHS) is issuing a fourth extension of telemedicine flexibilities for the prescribing of controlled medications through December 31, 2026.
- Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients (opens the source in a new tab)
In the January 17, 2025, issue of the Federal Register, the Drug Enforcement Administration and the Department of Health and Human Services published two final rules related to the practice of telemedicine, titled "Expansion of Buprenorphine Treatment via Telemedicine Encounte…
- Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients (opens the source in a new tab)
In the January 17, 2025, issue of the Federal Register, the Drug Enforcement Administration and the Department of Health and Human Services published two final rules related to the practice of telemedicine, titled "Expansion of Buprenorphine Treatment via Telemedicine Encounte…
- Continuity of Care via Telemedicine for Veterans Affairs Patients (opens the source in a new tab)
This final rule authorizes Department of Veterans Affairs (VA) practitioners acting within the scope of their VA employment to prescribe controlled substances via telemedicine to a VA patient with whom they have not conducted an in-person medical evaluation. VA practitioners a…
- Expansion of Buprenorphine Treatment via Telemedicine Encounter (opens the source in a new tab)
The Drug Enforcement Administration and the Department of Health and Human Services are amending their regulations to expand the circumstances under which practitioners registered by the Drug Enforcement Administration are authorized to prescribe schedule III-V controlled subs…
Related topics